Deficiencies in VPS35 are linked to an increased tau burden and late-onset AD (Vagnozzi et al., 2019; Wen et al., 2011) and are a known genetic risk in Parkinson’s disease (Vilariño-Güell et al., 2011). Here, MAPT is linked to Parkinson disease.